Funder
DEPARTMENT OF SCIENCE AND TECHNOLOGY, NEW DELHI, INDIA
Publisher
Springer Science and Business Media LLC
Reference95 articles.
1. Pant A, Singh J, Barnwal RP, Singh G, Singh B. Theranostic approach for the management of osteoporosis. Crit Rev Ther Drug Carrier Syst. 2023;40(3):95–121.
2. Yavropoulou MP, Makras P, Anastasilakis AD. Bazedoxifene for the treatment of osteoporosis. Expert Opin Pharmacother. 2019;20(10):1201–10.
3. Sree KSN, Dengale SJ, Mutalik S, Bhat K. Raloxifene HCl–quercetin co-amorphous system: preparation, characterization, and investigation of its behavior in phosphate buffer. Drug Dev Ind Pharm. 2022;48(6):227–38.
4. Arbuthnot GN, Dalder BW, Hartauer KJ, Wayne DL, Stratford RE. Raloxifene salts and solvates, formulations containing same, and methods for their preparation. 1996;Hungarian Patent, HU9902750A2.
5. Vora D, Dandekar A, Bhattaccharjee S, Singh ON, Agrahari V, Peet MM, Doncel GF, Banga AK. Formulation development for transdermal delivery of raloxifene, a chemoprophylactic agent against breast cancer. Pharmaceutics. 2022;14(3):1–14.